Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency

NCT02019667 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

19

Enrollment

NIH

Sponsor class

Conditions

Metabolic Disease
Seizures

Interventions

DRUG: SGS-742
DRUG: Placebo

Sponsor

National Institute of Neurological Disorders and Stroke (NINDS)